Immunovant 

Yahoo Finance • 3 days ago

Top Buys by Directors: Manheimer's $100.4K Bet on NTST

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earne... Full story

Yahoo Finance • 24 days ago

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s o... Full story

Yahoo Finance • last month

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story

Yahoo Finance • last month

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story

Yahoo Finance • 2 months ago

Immunovant GAAP EPS of -$0.71

* Immunovant press release [https://seekingalpha.com/pr/20195717-immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended] (NASDAQ:IMVT [https://seekingalpha.com/symbol/IMVT]): Q1 GAAP EPS of -$0.71 misse... Full story

Yahoo Finance • 2 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025All other clinical trials in previously announced six... Full story

Yahoo Finance • 2 months ago

OmniAb Q2 2025 slides: Partner growth accelerates despite revenue decline

OmniAb Inc. (NASDAQ:OABI) presented its second-quarter 2025 financial results and business update on August 6, revealing a company experiencing robust partner and program growth despite financial challenges. The antibody discovery platform... Full story

Yahoo Finance • 3 months ago

Immunovant (IMVT) chief technology officer Stout sells $26k in stock

Immunovant, Inc. (NASDAQ:IMVT) Chief Technology Officer Jay S. Stout, sold 1,519 shares of common stock on July 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average p... Full story

Yahoo Finance • 3 months ago

Goldman Sachs resumes Immunovant stock coverage with Neutral rating

Investing.com - Goldman Sachs resumed coverage of Immunovant (NASDAQ:IMVT) with a Neutral rating and set an $18.00 price target, close to InvestingPro’s Fair Value calculation. The company, currently valued at nearly $3 billion, trades wit... Full story

Yahoo Finance • 4 months ago

Roivant Sciences' president Venker sells $1.15 million in shares

Eric Venker, President and COO of Roivant Sciences (NASDAQ:ROIV), sold 100,000 common shares of the company on June 20, 2025, for $11.45 each, totaling $1.15 million. The transaction occurred near the stock’s current trading price of $11.5... Full story

Yahoo Finance • 4 months ago

Immunovant GAAP EPS of -$0.64 beats by $0.06

* Immunovant press release [https://seekingalpha.com/pr/20119506-immunovant-provides-corporate-updates-and-reports-financial-results-for-the-fourth-quarter] (NASDAQ:IMVT [https://seekingalpha.com/symbol/IMVT]): Q4 GAAP EPS of -$0.64 beat... Full story

Yahoo Finance • 6 months ago

Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?

We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other best low cost stocks to buy according to bi... Full story

Yahoo Finance • 7 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm... Full story

Yahoo Finance • 7 months ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm... Full story

Yahoo Finance • 7 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webca... Full story

Yahoo Finance • 7 months ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webca... Full story

Yahoo Finance • 8 months ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves’ disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinject... Full story

Yahoo Finance • last year

Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?

We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the dip. Capital markets demonstrated inc... Full story

Yahoo Finance • 2 years ago

Should You Invest in Immunovant (IMVT)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% (Institutional Shares) in the quarter compared to... Full story

Yahoo Finance • 2 years ago

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled O... Full story